The Future of Hemophilia Treatment: Longer-Acting Factor Concentrates versus Gene Therapy

Seminars in Thrombosis and Hemostasis

Volumn 42, Issue 5, 2016, Pages 513-517

  Giangrande, Paul ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

concentrates; gene therapy; hemophilia; longer acting; therapy

Indexed keywords

ALIPOGENE TIPARVOVEC; BLOOD CLOTTING FACTOR CONCENTRATE; GENE THERAPY AGENT; LENTIVIRUS VECTOR; LONG ACTING DRUG; PARVOVIRUS VECTOR; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; RETROVIRUS VECTOR; BLOOD CLOTTING FACTOR 9;

ARTICLE; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG SAFETY; FUTUROLOGY; GENE THERAPY; HEMOPHILIA; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT RESPONSE; BLOOD; DEPENDOPARVOVIRUS; GENE VECTOR; GENETICS; HEMOPHILIA A; PROCEDURES;

DEPENDOVIRUS; FACTOR IX; GENETIC THERAPY; GENETIC VECTORS; HEMOPHILIA A; HUMANS;

EID: 84966669624     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0036-1579637     Document Type: Article

References (22)

1. Den Uijl I. EM, Mauser Bunschoten E. P., Roosendaal G., et al. Clinical severity of haemophilia A: does the classification of the 1950s still stand? Haemophilia: 2011; 17 6 849 853
2. Skinner M. W. WFH: closing the global gap-achieving optimal care. Haemophilia: 2012; 18 04 1 12
3. Collins P. W., Young G., Knobe K., et al. paradigm 2 Investigators. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood: 2014; 124 26 3880 3886
4. Mahdi A. J., Obaji S. G., Collins P. W. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. Br J Haematol: 2015; 169 6 768 776
5. Shapiro A. D., Ragni M. V., Valentino L. A., et al. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood: 2012; 119 3 666 672
6. Powell J. S., Pasi K. J., Ragni M. V., et al. B-LONG Investigators. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med: 2013; 369 24 2313 2323
7. Potgieter J. J., Damgaard M., Hillarp A. One-stage vs. chromogenic assays in haemophilia A. Eur J Haematol: 2015; 94 77 38 44
8. Dodt J., Hubbard A. R., Wicks S. J., et al. Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators. Haemophilia: 2015; 21 4 543 549
9. Stennicke H. R., Kjalke M., Karpf D. M., et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood: 2013; 121 11 2108 2116
10. Lei T. C., Scott D. W. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. Blood: 2005; 105 12 4865 4870
11. Carmen I. H. A death in the laboratory: the politics of the Gelsinger aftermath. Mol Ther: 2001; 3 4 425 428
12. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science: 2003; 302 5644 415 419
13. Howe S. J., Mansour M. R., Schwarzwaelder K., et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest: 2008; 118 9 3143 3150
14. Brimble M. A., Reiss U. M., Nathwani A. C., Davidoff A. M. New and improved AAVenues: current status of hemophilia B gene therapy. Expert Opin Biol Ther: 2015; 2015 1 14
15. Nathwani A. C., Tuddenham E. G., Rangarajan S., et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med: 2011; 365 25 2357 2365
16. Nathwani A. C., Reiss U. M., Tuddenham E. G., et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med: 2014; 371 21 1994 2004
17. Liu Q., Huang W., Zhang H., et al. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors. Gene Ther: 2014; 21 8 732 738
18. Calcedo R., Morizono H., Wang L., et al. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol: 2011; 18 9 1586 1588
19. Han X., Ni W. Cost-Effectiveness Analysis of Glybera for the treatment of lipoprotein lipase deficiency. Value Health: 2015; 18 7 A756
20. Ylä-Herttuala S. Glybera's second act: the curtain rises on the high cost of therapy. Mol Ther: 2015; 23 2 217 218
21. Huch M., Gehart H., van Boxtel R., et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell: 2015; 160 1-2 299 312
22. Park C. Y., Kim D. H., Son J. S., et al. Functional correction of large factor VIII gene chromosomal inversions in hemophilia A patient-derived iPSCs using CRISPR-Cas9. Cell Stem Cell: 2015; 17 2 213 220